Developing and implementing a new prison-based buprenorphine treatment program

Journal of Offender Rehabilitation

Volumn 49, Issue 2, 2010, Pages 91-109

  Kinlock, Timothy W ^a   Gordon, Michael S ^b   Schwartz, Robert P ^b   Fitzgerald, Terrence T ^a  

^a UNIVERSITY OF BALTIMORE   (United States)

^b Friends Researh Institute Inc   (United States)

Author keywords

Buprenorphine; Prison; Substance abuse

Indexed keywords

EID: 75849134168     PISSN: 10509674     EISSN: 15408558     Source Type: Journal    
DOI: 10.1080/10509670903534951     Document Type: Article

References (37)

1. Albizu-Garcia, C., Caraballo Correa, G., Hernandez Viver, A. D., Kinlock, T.W., Gordon, M.S., Antron Avila, C., et al. (2007). Buprenorphine-naloxone treatment for pre-release opioid-dependent inmates in Puerto Rico. Journal of Addiction Medicine, 1, 126-132.
2. Amass, L., Kamien, J. B., & Mikulich, S. K. (2000). Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug and Alcohol Dependence, 58(1/2), 143-152.
3. American Association for the Treatment of Opioid Dependence (AATOD). (2004). AATOD's five-year plan for methadone treatment in the United States. Retrieved July 2009, from www.aatod.org
4. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders. Washington, DC: Author.
5. Binswanger, I. A., Stern, M. F., Deyo, R. A., Heagerty, P. J., Cheadle, A., Elmore, J. G., et al. (2007). Release from prison-a high risk of death for former inmates. New England Journal of Medicine, 356, 157-165.
6. Center for Substance Abuse Treatment (CSAT). (2004). Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction (Treatment Improvement Protocol [TIP] Series 40, DHHS Publication No. [SMA] 043939). Rockville, MD: Substance Abuse and Mental Health Services Administration.
7. Centers for Disease Control. (2006). Epidemiology of HIV/AIDS-United States, 1981. Morbidity and Mortality Weekly Report, 55, 589-592.
8. Farrell, M., & Marsden, J. (2008). Acute risk of drug-related death among newly released prisoners in England and Wales. Addiction, 103, 251-255.
9. Fiscella, K., Moore, A., Engerman, J., & Meldrum, S. (2004). Jail management of arrestees/inmates enrolled in community methadone maintenance programs. Journal of Urban Health, 81, 645-654.
10. Hagan, H., Snyder, N., Hough, E., Yu, T. J., McKeirnan, S., Boase, J., et al. (2002). Case-reporting of acute hepatitis B and C among injection drug users. Journal of Urban Health, 79, 579-585.
11. Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000). A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New England Journal of Medicine, 343, 1290-1297.
12. Jurgens, R. (2004). Is the world finally waking up to HIV/AIDS in prisons? A report from the 15th International AIDS Conference. Infectious Disease in Corrections Report, 9, 1-4.
13. Karberg, J., & James, D. (2005). Substance dependence, abuse, and treatment of jail inmates, 2002. Washington, DC: U.S. Department of Justice, Office of Justice Programs, Bureau of Justice Statistics.
14. Kinlock, T. W., Battjes, R. J., & Schwartz, R. P. (2005a). A novel opioid agonist program for prisoners: Report of post-release outcomes. American Journal of Drug and Alcohol Abuse, 31, 433-454.
15. Kinlock, T. W., & Gordon, M. S. (2006). Substance abuse treatment: New research. In L. A. Bennett (Ed.), New topics in substance abuse (pp. 73-111). New York, NY: Nova.
16. Kinlock, T. W., Gordon, M. S., Schwartz, R. P., Fitzgerald, T. T., & O'Grady, K. E. (2009). A randomized clinical trial of methadone maintenance for prisoners: Results at 12 months post-release. Journal of Substance Abuse Treatment, 37, 277-285.
17. Kinlock, T. W., O'Grady, K. E., & Hanlon, T. E. (2003). Prediction of the criminal activity of incarcerated drug-abusing offenders. Journal of Drug Issues, 33, 897-920.
18. Kinlock, T. W., Schwartz, R. P., & Gordon, M. S. (2005b). The significance of interagency collaboration in developing opioid agonist programs for inmates. Corrections Compendium, 30(6-9), 28-30.
19. Kleber, H. D. (2008). Methadone maintenance 4 decades later: Thousands of lives saved but still controversial. Journal of the American Medical Association, 300,2303-2305.
20. Levasseur, P., Marzo, J. N., Ross, N., & Blatier, C. (2002). Frequency of re-incarcerations in the same detention center: Role of substitution therapy: A preliminary retrospective analysis. Annales Medecine Interne, 153, S14-S19.
21. Magura, S., Lee, J. D., Hershberger, J., Joseph, H., Marsch, L., Shropshire, C., et al. (2009). Buprenorphine and methadone maintenance in jail and post release: A randomized clinical trial. Drug and Alcohol Dependence, 99, 222-230.
22. Magura, S., Rosenblum, A., Lewis, C., & Joseph, H. (1993). The effectiveness of in-jail methadone maintenance. Journal of Drug Issues, 23, 75-99.
23. Mattick, R. P., Ali, R., White, J. M., O'Brien, S., Wolk, S., & Danz, C. (2003). Bupre- norphine versus methadone maintenance therapy: A randomized double blind trial with 405 opioid-dependent patients. Addiction, 98, 441-452.
24. Miller, J. M., Koons-Witt, B. A., & Ventura, H. E. (2004). Barriers to evaluating the effectiveness of drug treatment behind bars. Journal of Criminal Justice, 32, 75-83.
25. Minton, T. C., & Sabol, W. J. (2009). Jail inmates at midyear 2008: Statistical tables. Washington, DC: U.S. Department of Justice, Office of Justice Programs, Bureau of Justice Statistics.
26. Montoya, I. D., Gorelick, D. A., Preston, K. A., Schroeder, J. R., Umbricht, A., Cheskin, L. J., et al. (2004). Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clinical Pharmacology Therapeutics, 7, 34-48.
27. Mumola, C., & Karberg, J. (2006). Drug use and dependence, state and federal prisoners, 2004. Washington, DC: U.S. Department of Justice, Office of Justice Programs.
28. Office of National Drug Control Policy. (2001). The National Drug Control Strategy Annual Report. Washington, DC: Executive Office of the President, Office of National Drug Control Policy.
29. Pelissier, B., & Jones, N. (2005). A review of gender differences among substance abusers. Crime and Delinquency, 51, 345-372.
30. Prendergast, M. L., & Wexler, H. L. (2004). Correctional substance abuse treatment programs in California: A historical perspective. The Prison Journal, 84, 8-35.
31. Rich, J. D., Boutwell, A. E., Shield, D. C., Key, R. G., McKenzie, M., Clarke, J. G., et al. (2005). Attitudes and practices regarding the use of methadone in U.S. state and federal prisons. Journal of Urban Health, 82, 411-419.
32. Smith-Rohrberg, D., Bruce, R. D., & Altice, F. L. (2004). Research note-Review of corrections-based therapy for opiate-dependent patients: Implications for Buprenorphine treatment among correctional populations. Journal of Drug Issues, 34, 451-480.
33. Strain, E. C., Stitzer, M. L., Liebsen, I. A., & Bigelow, G. E. (1994). Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry, 151, 1025-1030.
34. Substance Abuse and Mental Health Services Administration (SAMHSA). (2000). Year-end 1999 emergency department data from the Drug Abuse Warning Network. Rockville, MD: Author.
35. Tomasino, V., Swanson, A. J., Nolan, J., & Shuman, M. (2001). The Key Extended Entry Program (KEEP): A methadone treatment program for opiate-dependent inmates. The Mount Sinai Journal of Medicine, 68, 14-20.
36. Welsh, W. N., & Zajac, G. (2004). Building an effective research partnership between a university and a state correctional agency: Assessment of drug treatment in Pennsylvania prisons. The Prison Journal, 84, 143-170.
37. West, H. C., & Sabol, W. J. (2009). Prison inmates at midyear 2008: Statistical tables. Washington, DC: U.S. Department of Justice, Office of Justice Programs, Bureau of Justice Statistics.